GlobeImmune is a biopharmaceutical company pioneering the discovery, development and manufacturing of potent, targeted molecular immunotherapies called Tarmogens for the treatment of infectious diseases and cancer.

Tarmogens (Targeted Molecular Immunogens) are whole, heat-killed recombinant Saccharomyces cerevisiae  yeast genetically modified to express one or more protein targets that stimulate the immune system against diseased cells.  The whole heat-killed yeast, with the antigen expressed inside, is the product that is administered to the patient.   Tarmogens program the cytotoxic T cells (a.k.a. killer T cells) in the patient's immune system to eliminate diseased cells containing the antigen(s). GlobeImmune's patented Tarmogen platform has a number of advantages over current approaches because Tarmogens generate a potent T cell response, are not neutralized by the host immune system upon repeated administration, do not require a custom vaccine approach and are simple to manufacture.

The Company's lead product , GI-5005 a Tarmogen for the treatment of chronic hepatitis C infection has completed a placebo-controlled, dose-escalation Phase 1b clinical trial.  A randomized, placebo controlled Phase 2 trial in combination with standard of care will begin in the second half of 2007.    GI-4000, a Tarmogen for the treatment of various mutated Ras-mediated cancers, is in a randomized, placebo-controlled, multi-center Phase 2 trial for the treatment of patients with resectable pancreas cancer in combination with adjuvant gemcitabine. 

Click here to download
the GlobeImmune
2-page Fact Sheet

Click here to download
a copy of the GI-5005
Phase 1b poster